These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4599465)

  • 61. Studies on goat anti-CBA thymocyte globulin: the large scale preparation, purification and testing of anti-lymphocyte serum and anti-lymphocyte globulin.
    Fahey KJ
    Aust J Exp Biol Med Sci; 1973 Aug; 51(4):489-99. PubMed ID: 4202936
    [No Abstract]   [Full Text] [Related]  

  • 62. Antilymphocyte globulin prepared by precipitation with Rivanol in the treatment of acute rejection following allogenic renal transplantation in the dog.
    Husberg B; Carlsson S; Hellsten S; Liedberg CF; Nettelblad SC; Weiber A
    Scand J Urol Nephrol; 1972; 6(2):154-6. PubMed ID: 4557339
    [No Abstract]   [Full Text] [Related]  

  • 63. Immunosuppression and clinical organ transplantation.
    Calne RY
    Transplant Proc; 1974 Dec; 6(4 Suppl 1):49-51. PubMed ID: 4612904
    [No Abstract]   [Full Text] [Related]  

  • 64. Improvement in cadaveric renal transplant survival.
    Beaudoin JG; Guttmann RD; Morehouse DD; Knaack J; Chassot PG
    Arch Surg; 1973 Aug; 107(2):245-9. PubMed ID: 4578273
    [No Abstract]   [Full Text] [Related]  

  • 65. The effect of immunosuppressants on the development of Hymenolepis diminuta in mice.
    Hopkins CA; Subramanian G; Stallard H
    Parasitology; 1972 Aug; 65(1):111-20. PubMed ID: 5053035
    [No Abstract]   [Full Text] [Related]  

  • 66. The influence of route of ALG administration on canine renal allograft survival.
    Collste LG; Groth CG; Kashiwagi N; Schantz B
    Transplantation; 1971 Jul; 12(1):91-3. PubMed ID: 4932702
    [No Abstract]   [Full Text] [Related]  

  • 67. Late acute rejection in renal transplant recipients: response to steroid treatment.
    Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
    Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
    [No Abstract]   [Full Text] [Related]  

  • 68. Comparison of the efficacy of immunosuppressive regimens on orthotopic heart allografts.
    Kondo Y; Grogan JB; Cockrell JV; Kuramochi T; Smith GV; Hardy JD
    J Thorac Cardiovasc Surg; 1974 Apr; 67(4):612-20. PubMed ID: 4594431
    [No Abstract]   [Full Text] [Related]  

  • 69. Non-specific and adaptive immunity in renal transplantation.
    Alexander JW; McCoy HV; Phair JP; Altemeier WA
    Transplant Proc; 1969 Mar; 1(1):283-6. PubMed ID: 4944227
    [No Abstract]   [Full Text] [Related]  

  • 70. Experimental kidney transplantation.
    Murphy GP; Grafton TS
    Lab Anim Sci; 1973 Feb; 23(1):97-102. PubMed ID: 4347767
    [No Abstract]   [Full Text] [Related]  

  • 71. Reduction in the incidence of early rejection in cadaveric renal allograft recipients treated with ATGAM induction and sequential mycophenolate mofetil.
    Florence LS; Howard DR; Chapman PH; Lieberman J; Perkinson DT; Marks WH
    Transplant Proc; 1997; 29(1-2):313-4. PubMed ID: 9123016
    [No Abstract]   [Full Text] [Related]  

  • 72. Suppression of canine renal allograft rejection with antilymphocyte serum.
    Clunie GJ; Howard RR; Robinson E; Morton H
    Aust N Z J Surg; 1969 Aug; 39(1):68-71. PubMed ID: 4898557
    [No Abstract]   [Full Text] [Related]  

  • 73. Clinical aspects of allograft rejection.
    Williams GM
    Transplant Proc; 1974 Dec; 6(4 Suppl 1):71-7. PubMed ID: 4612907
    [No Abstract]   [Full Text] [Related]  

  • 74. DEAE-cellulose batch production of immunoglobulin G (IgG) from antilymphocyte serum (ALS).
    Mogi G; Harvey JE; Ogura JH
    Laryngoscope; 1972 Jun; 82(6):998-1006. PubMed ID: 4113861
    [No Abstract]   [Full Text] [Related]  

  • 75. Triple immunosuppressive therapy in immunologic high-risk renal allograft recipients.
    Cole E; Robinson C; Bear R
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2026-7. PubMed ID: 2652662
    [No Abstract]   [Full Text] [Related]  

  • 76. Comparison of 10-day and 21-day ATG-antirejection treatment in renal transplant patients treated with either cyclosporine or azathioprine as basic immunosuppression.
    Hoitsma AJ; Tiggeler RG; Wetzels JF; Berden JH; Koene RA
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1732-3. PubMed ID: 2652566
    [No Abstract]   [Full Text] [Related]  

  • 77. Comparison of standard immunosuppression with adjuvant antilymphoblast globulin in primary cadaver kidney transplant survival.
    Barry JM; Frankus E; Norman DJ; Bennett WM
    Urology; 1982 Mar; 19(3):287-9. PubMed ID: 7039064
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is sequential low-dose immunotherapy the preferred treatment in cadaveric renal transplantation?
    Posner MP; Mendez-Picon G; King A; Nelson KP; Spicer HG; Lee HM
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1594-7. PubMed ID: 2652519
    [No Abstract]   [Full Text] [Related]  

  • 79. Antithymocyte globulin in renal transplant recipients. Report of a prospective randomized controlled trial.
    Chatterjee SN
    Arch Surg; 1976 Jun; 111(6):680-3. PubMed ID: 58651
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The adjunctive value of equine antithymocyte membrane globulin in a randomized study of patients undergoing cadaveric renal transplantation.
    Diethelm AG; Blackstone E; Whelchel JD; Pass RF; Chambers L; Phillips SJ; Thiry C
    Transplant Proc; 1979 Mar; 11(1):27-30. PubMed ID: 377644
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.